Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

References

• Glenny AT, Pope CG, Waddington H, Wallace U. The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol.29, 31–40 (1926).
   Google Scholar
• Shirodkar S, Hutchinson RL, Perry DL, White JL, Hem SL. Aluminum compounds used as adjuvants in vaccines. Pharm. Res.7, 1282–1288 (1990).
   PubMed Web of Science ®Google Scholar
• Stumm W. Chemistry of the Solid-Water Interface: Processes at the Mineral-Water and Particle-Water Interface in Natural Systems. John Wiley and Sons, NY, USA 13–38 (1992).
   Google Scholar
• Iyer S, HogenEsch H, Hem SL. Effect of the degree of phosphate substitution in aluminum hydroxide adjuvant on the adsorption of phosphorylated proteins. Pharm. Dev. Technol.8, 81–86 (2003).
   PubMed Web of Science ®Google Scholar
• Jiang D, Johnston CT, Hem SL. Using rate of acid neutralization to characterize aluminum phosphate adjuvant. Pharm. Dev. Technol.8, 349–356 (2003).
   PubMed Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients (5th Edition). Pharmaceutical Press London, UK 36, 40 (2006).
   Google Scholar
• Zhao Q, Sitrin R. Surface phosphophilicity of aluminum-containing adjuvants probed by their efficiency for catalyzing the P–O bond cleavage with chromogenic and fluorogenic substrates. Anal. Biochem.295, 76–81 (2001).
   PubMed Web of Science ®Google Scholar
• Romero Mendez IZ, Shi Y, HogenEsch H, Hem SL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine25, 825–833 (2007).
   PubMed Web of Science ®Google Scholar
• Johnston CT, Wang S-L, Hem SL. Measuring the surface area of aluminum hydroxide adjuvant. J. Pharm. Sci.91, 1702–1706 (2002).
   PubMed Web of Science ®Google Scholar
• Morefield GL, HogenEsch H, Robinson JP, Hem SL. Distribution of adsorbed antigen in mono-valent and combination vaccines. Vaccine22, 1973–1984 (2004).
   PubMed Web of Science ®Google Scholar
• Peek LJ, Martin TT, Nation CE, Pegram SA, Middaugh CR. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J. Pharm. Sci.96, 547–557 (2007).
   PubMed Web of Science ®Google Scholar
• Seeber SJ, White JL, Hem SL. Predicting the adsorption of proteins by aluminum-containing adjuvants. Vaccine9, 201–203 (1991).
   PubMed Web of Science ®Google Scholar
• Al-Shakhshir RH, Regnier FE, White JL, Hem SL, Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminum-containing adjuvants. Vaccine13, 41–44 (1995).
   PubMed Web of Science ®Google Scholar
• Morefield GL, Jiang D, Romero Mendez IZ, Geahlin RL, HogenEsch H, Hem SL. Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid. Vaccine23, 1502–1506 (2005).
   PubMed Web of Science ®Google Scholar
• Rinella JV Jr, White JL, Hem SL. Effect of anions on model aluminum-adjuvant-containing vaccines. J. Colloid Interface Sci.172, 121–130 (1995).
   Web of Science ®Google Scholar
• Seeber SJ, White JL, Hem SL. Solubilization of aluminum-containing adjuvants by constituents of interstitial fluid. J. Parenter. Sci. Technol.45, 156–159 (1991).
   PubMedGoogle Scholar
• Heimlich JM, Regnier FE, White JL, Hem SL. The in vitro displacement of adsorbed model antigens from aluminum-containing adjuvants by interstitial proteins. Vaccine17, 2873–2881 (1999).
   PubMed Web of Science ®Google Scholar
• Jiang D, Morefield GL, HogenEsch H, Hem SL. Relationship of adsorption mechanism of antigens by aluminum-containing adjuvants to in vitro elution in interstitial fluid. Vaccine24, 1665–1669 (2006).
   PubMed Web of Science ®Google Scholar
• Jendrek S, Little SF, Hem S, Mitra G, Giardina S. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine21, 3011–3018 (2003).
   PubMed Web of Science ®Google Scholar
• DePaz RA, Henderson I, Advant SJ. Formulation of botulinum neurotoxin heavy chain fragments for vaccine development: mechanisms of adsorption to an aluminum-containing adjuvant. Vaccine23, 4029–4035 (2005).
   PubMed Web of Science ®Google Scholar
• Iyer S. Robinett RSR, HogenEsch H, Hem SL. Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant. Vaccine22, 1475–1479 (2004).
   PubMed Web of Science ®Google Scholar
• Jones LS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J. Biol. Chem.280, 13406–13414 (2005).
   PubMed Web of Science ®Google Scholar
• Kanra G. Viviani S, Yurdakok K et al. Effect of aluminum adjuvants on safety and immunogneicity of Haemophilus influenzae type b-CRM 197 conjugate vaccine. Pediatr. Int.45, 314–318 (2003).
   PubMed Web of Science ®Google Scholar
• Berthold I, Pombo M-L, Wagner L, Arciniega JL. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine23, 1993–1999 (2005).
   PubMed Web of Science ®Google Scholar
• Dong A, Jones LS, Kerwin BA, Krishnan S, Carpenter JF. Secondary structures of proteins adsorbed onto aluminum hydroxide: infrared spectroscopic analysis of proteins from low solution concentrations. Anal. Biochem.351, 282–289 (2006).
   PubMed Web of Science ®Google Scholar
• Wittayanakullluk A, Jiang D, Regnier F, Hem SL. Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen. Vaccine22, 1172–1176 (2004).
   PubMed Web of Science ®Google Scholar
• Burrell LS, White JL, Hem SL. Stability of aluminum-containing adjuvants during aging at room temperature. Vaccine18, 2188–2192 (2000).
   PubMed Web of Science ®Google Scholar
• World Health Organization Group. Temperature Sensitivity of Vaccines. WHO Press, Geneva, Switzerland (2006).
   Google Scholar
• Maa Y-F, Zhao L, Payne LG, Chen D. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J. Pharm. Sci.92, 319–332 (2003).
   PubMed Web of Science ®Google Scholar
• Maa Y-F, Shu C, Ameri M et al. Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization. Pharm. Res.20, 969–977 (2003).
   PubMed Web of Science ®Google Scholar
• Burrell LS, Lindblad EB, White JL, Hem SL. Stability of aluminum-containing adjuvants to autoclaving. Vaccine17, 2599–2603 (1999).
   PubMed Web of Science ®Google Scholar
• Rinella JV Jr, White JL, Hem SL. Effect of pH on the elution of model antigens from aluminum-containing adjuvants. J. Colloid Interface Sci.205, 161–165 (1998).
   PubMed Web of Science ®Google Scholar
• Flarend RE, Hem SL, White JL et al. In vivo absorption of aluminum-containing vaccine adjuvants using 26Al. Vaccine15, 1314–1318 (1997).
   PubMed Web of Science ®Google Scholar
• White RG, Coons AH, Connolly JM. Studies on antibody production. III. The alum granuloma. J. Exp. Med.102, 73–82 (1955).
   PubMed Web of Science ®Google Scholar
• Holt LB. Developments in Diphtheria Prophylaxis. W Heinemann Medical Books Ltd, London, UK 67 (1950).
   Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature392, 245–252 (1998).
   PubMed Web of Science ®Google Scholar
• Goto N, Akama K. Histopathological studies of reactions in mice injected with aluminum-adsorbed tetanus toxoid. Microbiol. Immunol.26, 1121–1132 (1982).
   PubMed Web of Science ®Google Scholar
• Goto N, Kato H, Maeyama J et al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine15, 1364–1371 (1997).
   PubMed Web of Science ®Google Scholar
• Walls RS. Eosinophil response to alum adjuvants: involvement of T-cells in not-antigen-dependent mechanisms. Proc. Soc. Exp. Biol. Med.156, 431–435 (1977).
   PubMed Web of Science ®Google Scholar
• Verdier F, Burnett R, Michelet-Habchi C, Moretto P, Fievet-Groyne F, Sauzeat E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the cynomolgus monkey. Vaccine23, 1359–1367 (2005).
   PubMed Web of Science ®Google Scholar
• Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity11, 753–761 (1999).
   PubMed Web of Science ®Google Scholar
• Glenny AT, Buttle AH, Stevens MF. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea pigs: toxoid precipitated with alum. J. Pathol. Bacteriol.34, 267–275 (1931).
   Google Scholar
• HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine20(Suppl. 3), 534–539 (2002).
   Google Scholar
• Iyer S, HogenEsch H, Hem SL. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine21, 1219–1223 (2003).
   PubMed Web of Science ®Google Scholar
• Gupta RK, Chang A-C, Griffin P, Rivera R, Siber GR. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine14, 1412–1416 (1996).
   PubMed Web of Science ®Google Scholar
• MacLean DS, Robertson JD, Jay M. Monitoring the retention of a protein antigen in complete Freund’s adjuvant, alum and Pluronic R-127 gel formulations by x-ray fluorescence. Pharm. Dev. Technol.6, 241–246 (2001).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, DeWill CM, Chastain M et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine18, 18–28 (1999).
   PubMed Web of Science ®Google Scholar
• Wang S, Fisher K, Smith JG et al. Enhanced type 1 immune response to hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate. Vaccine18, 1227–1235 (2000).
   PubMed Web of Science ®Google Scholar
• Kwissa M, Lindblad EB, Schirmbeck R, Reimann J. Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response. J. Mol. Med.81, 502–510 (2003).
   PubMed Web of Science ®Google Scholar
• Mackay CR. Homing of naive, memory and effector lymphocytes. Curr. Opin. Immunol.5, 423–427 (1993).
   PubMed Web of Science ®Google Scholar
• Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4+ T-cells in the whole body. Nature410(6824), 101–105 (2001).
   PubMed Web of Science ®Google Scholar
• Gretz JE, Norbury CC, Anderson AO, Proudfoot AE, Shaw S. Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J. Exp. Med.192, 1425–1440 (2000).
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol.8, 348–354 (1996).
   PubMed Web of Science ®Google Scholar
• Mannhalter JW, Neychev HO, Zlabinger GJ, Ahmad R, Eibl MM. Modulation of the human immune response by non-toxic and non-pyrogenic adjuvant aluminum hydroxide: effect on antigen uptake and antigen presentation. Clin. Exp. Immunol.61, 143–151 (1985).
   PubMed Web of Science ®Google Scholar
• Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine23, 1588–1595 (2005).
   PubMed Web of Science ®Google Scholar
• Barton GM, Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr. Opin. Immunol.14, 380–383 (2002).
   PubMed Web of Science ®Google Scholar
• Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol.81, 1–5 (2007).
   PubMed Web of Science ®Google Scholar
• Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol.2, 947–950 (2001).
   PubMed Web of Science ®Google Scholar
• Gavin AL, Hoebe K, Duong B et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science314(5807), 1936–1938 (2006).
   PubMed Web of Science ®Google Scholar
• Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun.69, 1151–1159 (2001).
   PubMed Web of Science ®Google Scholar
• Wilcock LK, Francis JN, Durham SR. Aluminum hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin. Exp. Allergy34, 1373–1378 (2004).
   PubMed Web of Science ®Google Scholar
• Rimaniol AC, Gras G, Verdier F et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine22, 3127–3135 (2004).
   PubMed Web of Science ®Google Scholar
• Sokolovska A, Hem SL, HogenEsch H. Activation of dendritic cells and induction of CD4+ T-cell differentiation by aluminum-containing adjuvants. Vaccine25, 4574–4585 (2007).
   Google Scholar
• Hansen B, Sokolovska A, HogenEsch H, Hem SL. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine25(36), 6618–6624 (2007).
   PubMed Web of Science ®Google Scholar
• Dillon SB, Demuth SG, Schneider MA et al. Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminum hydroxide adjuvant. Vaccine10, 309–318 (1992).
   PubMed Web of Science ®Google Scholar
• Wijburg OL, van den Dobbelsteen GP, Vadolas J, Sanders A, Strugnell RA, van Rooijen N. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens. Eur. J. Immunol.28, 479–487 (1998).
   PubMed Web of Science ®Google Scholar
• Sheikh NA, Rajananthanan P, Attard GS, Morrow WJ. Generation of antigen specific CD8+ cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants. Vaccine17, 2974–2982 (1999).
   PubMed Web of Science ®Google Scholar
• Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today20, 561–567 (1999).
   PubMedGoogle Scholar
• Burns K, Martinon F, Tschopp J. New insights into the mechanism of IL-1β maturation. Curr. Opin. Immunol.15, 26–30 (2003).
   PubMed Web of Science ®Google Scholar
• Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1β and IL-18 release. J. Immunol.178, 5271–5276 (2007).
   PubMed Web of Science ®Google Scholar
• Peek LJ, Brey RN, Middaugh CR. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine. J. Pharm. Sci.96, 44–60 (2007).
   PubMed Web of Science ®Google Scholar
• Peek LJ, Brandau DT, Jones LS, Foshi SB, Middaugh CR. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine24, 5839–5851 (2006).
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature408, 740–745 (2000).
   PubMed Web of Science ®Google Scholar
• Davis HL, Weeranta R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol.160, 870–876 (1998).
   PubMed Web of Science ®Google Scholar
• Wang S, Liu X, Caulfield MJ. Adjuvant synergy in the response to hepatitis B vaccines. Vaccine21, 4297–4306 (2003).
   PubMed Web of Science ®Google Scholar
• Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science316, 1628–1632 (2007).
   PubMed Web of Science ®Google Scholar
• Thoelen S, Van Damme P, Mathei P et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine16, 708–714 (1998).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (ASO4) compared to aluminium salt only. Vaccine24, 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Vernacchio L, Bernstein H, Pelton S et al. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine20, 3658–3667 (2002).
   PubMed Web of Science ®Google Scholar
• Jankovic D, Caspar P, Zweig M et al. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J. Immunol.159, 2409–2417 (1997).
   PubMed Web of Science ®Google Scholar